Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing
Cambridge, UK - Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd.
Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board
Leading expert in DUB biology and drug discovery further strengthens Ubiquigent’s DUB-focused capabilities and internal pipelineDundee, UK - Ubiquigent Limited (Ubiquigent), a drug disco
Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines.
Global Access Diagnostics joins consortium to co-develop on-farm rapid test for calf pneumonia, RaDiCal
Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, today announced the development of RaDiCal, a one-step molecular lateral flow test to enable rapid diagnosis of pneumonia, one of the most si
The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein
Antigen designed to support immunoassay and vaccine development applications
Shenandoah Biotechnology introduces expanded range of CTGrade recombinant proteins manufactured following cGMP practices
Shenandoah Biotechnology Inc., a FUJIFILM Irvine Scientific company and leading manufacturer of recombinant proteins, today announced it has expanded its CTGrade portfolio of cytokines and growth factors for cell a
Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents
Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits. These include fiv
The Native Antigen Company strengthens senior team to support growing product portfolio
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced two key appointments to its management team.
Fujifilm invests $188 million in new cell culture media manufacturing facility
FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.
The Native Antigen Company introduces new range of influenza antigens
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the
Bio-Rad introduces Pioneer™ Antibody Discovery Platform for therapeutic development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announces the launch of the Pioneer Antibody Discovery Platform, a new antibody discovery service specifically designed to develop best-in-class biologic candidates.
Pangaea Data awarded top tier co-sell partnership status by Microsoft
South San Francisco, USA - Pangaea Data, provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, announces that it has been awarded top tier co-sell partnership status by Microsoft, its highest level partner designation. Microsoft has also extended this status by making Pangaea a transactable…
Ubiquigent appoints Dr Hozefa Amijee as Head of Business Development
Dundee, UK - Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, announces the appointment of Dr Hozefa Amijee as Head of Business Development (BD).
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases.
Ubiquigent obtains exclusive license for UbiSite technology to strengthen its specialist drug discovery services
Dundee, UK - Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology.
Ubiquigent appoints Dr Sheelagh Frame, CSO, to its Board of Directors
New Board appointment supports Ubiquigent’s pursuit of novel DUB modulators as new therapeutics to address areas of high unmet medical need
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be used in FDA-authorized clinical trial
SANTA ANA, Calif., - FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, announces that its PRIME-XV Stem FreezIS DMSO-Free* cryopreservation medium is to be used as an excipient in a FDA-authorized clinical trial conducted by Vitro Biopharma.
Astrea Bioseparations introduces Nereus LentiHERO, a fit-for-purpose solution for lentiviral vector purification
Cambridge, UK - Astrea Bioseparations, a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, announces the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.
Yourgene Health Receives HSA approval for IONA Nx NIPT Workflow in Singapore
Manchester, UK - Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, announces it has received Health Sciences Authority (HSA) approval for its IONA® Nx NIPT Workflow in Singapore.
H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support
Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research.
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio-Rad, a global leader in life science research and clinical diagnostic products.
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the…
Bio-Rad introduces anti-evolocumab antibodies for use in preclinical and clinical drug development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, introduces a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. These sequence…
Bio-Rad extends range of StarBright Violet and UltraViolet Dyes for multiplex flow cytometry
HERCULES, Calif, — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, extends its range of StarBright Dyes to provide greater flexibility in multicolor flow cytometry panels. The StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 Dyes offer improved brightness with narrow excitation and emission profiles for…